#United States #San Francisco #oncology #J.P. Morgan #IDEAYA Biosciences

IDEAYA Biosciences Participation at the J.P. Morgan Healthcare Conference

IDEAYA Biosciences, Inc., listed on NASDAQ under IDYA, is making headlines with its announcement to participate in the prestigious 44th Annual J.P. Morgan Healthcare Conference set for January 12, 2026. This event is a critical platform for some of the leading firms in the healthcare sector, focusing on innovation, research, and development. The event will be held in San Francisco, California.

Key Presentation Details
The anticipated presentation will be led by Yujiro S. Hata, the Chief Executive Officer of IDEAYA Biosciences. Following the presentation, there will be a question and answer session led by Anupam Rama, Managing Director of US SMID Biotechnology Equity Research at J.P. Morgan. This two-part format is designed to provide investors and stakeholders with an insightful look into IDEAYA’s efforts and innovations in precision medicine oncology.

An audio webcast of the entire presentation will be accessible via the IDEAYA website, specifically under the "Investors/Events" section, as well as through the conference hosting platform. The company plans to ensure that the webcast remains available for a duration of 30 days post-event, allowing interested parties to review the insights shared during the conference.

About IDEAYA Biosciences
IDEAYA Biosciences prides itself on being a pioneer in the field of precision medicine, with a core focus on oncology. The organization is devoted to the discovery, development, and commercialization of transformative therapies for cancer treatment. Utilizing a comprehensive blend of small-molecule drug discovery, structural biology, and advanced bioinformatics, IDEAYA works on validating translational biomarkers that play a critical role in tailoring their therapies.

Their pipeline is particularly robust, featuring numerous product candidates aimed at synthetic lethality and antibody-drug conjugates (ADCs) for specific molecularly defined solid tumor indications. IDEAYA’s mission is to lead in offering cutting-edge therapies that are not just selective and effective, but also deeply personalized. Their goal is to significantly alter disease progression for cancer patients while improving overall clinical outcomes.

Looking Ahead
IDEAYA's commitment to innovation doesn't just end with one conference or presentation; rather, it is supported by ongoing research and potential new drug developments that continue to enhance the landscape of cancer treatment. As they prepare for the J.P. Morgan Healthcare Conference, stakeholders can expect to gain valuable insights into how the company plans to advance its initiatives and drive the future of precision oncology.

Forward-Looking Statements
In the spirit of transparency, IDEAYA reminds stakeholders that this press release contains forward-looking statements. These statements are inherently subject to risks and uncertainties that could cause actual results to differ noticeably. For those interested in understanding the associated risks related to IDEAYA’s business and initiatives, they are encouraged to review the company’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

Media and Investor Relations
For more information, IDEAYA encourages interested parties to reach out to Joshua Bleharski, Ph.D., Chief Financial Officer at IDEAYA Biosciences, for inquiries and further details regarding participation in the upcoming conference.